popular wires

What you need to know about contributing to your super.

Whilst equities hogged the limelight, the top-performing alternatives funds also delivered in FY25 - on both diversification and performance

Fund managers slashed cash levels to a decade-low of 3.9% as optimism soars to levels not seen since February, according to BofA.

Australian bonds experienced a resurgence, posting their best financial year since 2018/19. Some managers returned close to 10%.

Greg Sharenow, managing director and portfolio manager, charts the continued resilience of commodities and their low correlation with stocks and bonds amid recent...

Amid sticky inflation and geopolitical risk, these funds stood out by delivering income and stability when it mattered most.

Australia is now less sensitive to China, but Chinese growth is likely to be enough to keep the iron ore price elevated.

In a world chasing passive giants, Australian small caps shine with active alpha, sector diversity, and next-gen growth potential.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market.

As older Australians look for affordable housing, Aspen’s smart model provides both shelter and shareholder value.

Institutional demand has been fuelling Bitcoin’s comeback, potentially shifting crypto from speculation to strategic investment.

Rising inequality is distorting markets, powering US exceptionalism, and setting the stage for potential volatility ahead.

The June CPI report came in as expected, bringing the annual headline increase to 2.7%, a tick-up from last month’s 2.4% reading. Meanwhile, core inflation rose 2.9%,...

It was the old-world store of value and the new-age digital gold that stole the show in FY25.

Bloomberg is talking a once-in-a-generation copper trade. Get ready to be sold to! Traders want you to take the other side of this trade.

We unpack six key themes that stood out from over 30 meetings with prospective and existing investees across Europe, the UK and the US.

The RBA’s proposed surcharge ban and fee caps may reshape payments, but Visa and Mastercard are already positioned for the shift.

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term patient investors.

Explore U.S. economic trends: growth uncertainty and rising inflation risks.

In this series, we're profiling managers whose funds are constituents of the 20-Year Club (i.e. at least two decades of operation).